MAPK3
-
Official Full Name
MAPK3 mitogen-activated protein kinase 3
-
Synonyms
MAPK3; mitogen-activated protein kinase 3; PRKM3; ERK1; p44erk1; p44mapk; MAPK 1; MAP kinase 1; MAP kinase 3; MAP kinase isoform p44; insulin-stimulated MAP2 kinase; mitogen-activated protein kinase 1; extracellular signal-related kinase 1; extracellular signal-regulated kinase 1; microtubule-associated protein 2 kinase; ERT2; ERK-1; P44ERK1; P44MAPK; HS44KDAP; HUMKER1A; p44-ERK1; p44-MAPK; MGC20180;
- Recombinant Proteins
- Cell & Tissue Lysates
- Protein Pre-coupled Magnetic Beads
- Human
- Mouse
- Rat
- Zebrafish
- E.coli
- HEK293
- HEK293T
- Mammalian Cell
- Mammalian cells
- Flag
- GST
- His
- Fc
- Avi
- MBP
- Myc
- DDK
- Non
- Background
- Quality Guarantee
- Case Study
- Involved Pathway
- Protein Function
- Interacting Protein
- Other Resource
- MAPK3 Related Signal Pathway
What is MAPK3 protein?
MAPK3 (mitogen-activated protein kinase 3) gene is a protein coding gene which situated on the short arm of chromosome 16 at locus 16p11. The protein encoded by this gene is a member of the MAP kinase family. MAP kinases, also known as extracellular signal-regulated kinases (ERKs), act in a signaling cascade that regulates various cellular processes such as proliferation, differentiation, and cell cycle progression in response to a variety of extracellular signals. This kinase is activated by upstream kinases, resulting in its translocation to the nucleus where it phosphorylates nuclear targets. The MAPK3 protein is consisted of 379 amino acids and its molecular mass is approximately 43.1 kDa.
What is the function of MAPK3 protein?
Activation of MAPK3 requires both tyrosine and threonine phosphorylation that is mediated by MEK. MAPK3 is ubiquitously distributed in tissues with the highest expression in heart, brain and spinal cord. Activated MAPK3 translocates into the nucleus where it phosphorylates various transcription factors (e.g., Elk-1, c-Myc, c-Jun, c-Fos, and C/EBP beta). MAPK3 can respond to extracellular stimuli, such as growth factors, hormones, and neurotransmitters, and activate downstream target proteins through phosphorylation. It is also involved in the regulation of immune response and can be activated by inflammatory mediators such as TNF-α and IL-1β, thus inducing the occurrence and maintenance of inflammatory response. It can also be activated by a variety of carcinogenic factors, such as Ras mutation, PTEN deletion, etc., and then promote the proliferation, invasion and metastasis of tumor cells.
MAPK3 Related Signaling Pathway
MAPK3 is an important member of the MAPK family, which can respond to a variety of extracellular stimuli, such as growth factors, hormones, neurotransmitters, and activate downstream target proteins through phosphorylation, thereby mediating cell proliferation, differentiation, apoptosis and other biological processes. MAPK3 is located between RAS GTPase and MAPK1 in the member kinase cascade, and MAPK3 can be activated by Ras proteins, which activate MAPK1 through phosphorylation, thereby regulating a variety of cell biological responses. In addition, MAPK3 can also be involved in the regulation of PI3K/AKT signaling pathway and Wnt/β-catenin signaling pathway.
Fig1. The proposed signaling pathways involved in Kisspeptin-modulated cell invasion and migration in endometrial cancer cells. (Hsien-Ming Wu, 2024)
MAPK3 Related Diseases
MAPK3 is abnormally expressed in a variety of cancers, including breast cancer, lung cancer, and colorectal cancer. It can promote the proliferation, invasion and metastasis of tumor cells by activating MAPK/ERK signaling pathway. MAPK3 can promote neuronal survival and axon growth by activating MAPK/ERK signaling pathway, thus participating in the occurrence and development of Parkinson's disease, Alzheimer's disease and other diseases. It can also promote inflammatory response and immune response by activating NF-κB signaling pathway, thus participating in the occurrence and development of autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. In addition, the mutation of MAPK3 gene is associated with the occurrence of cardiovascular diseases such as hypertension and coronary heart disease.
Bioapplications of MAPK3
MAPK3 has important application value in many biological fields, and has important research significance for in-depth understanding of the mechanism of cell signaling, the mechanism of tumorigenesis, and the function and disease of nervous system and cardiovascular system. Therapeutic strategies targeting MAPK3 are also being investigated, such as the use of antibodies or small molecule inhibitors to inhibit its activity, thereby stopping tumor growth and metastasis.
High Purity
Fig1. SDS-PAGE (MAPK3-307H) (PROTOCOL for western blot)
.
Fig2. Activity Data. (MAPK3-307H)
Case study 1: Jia Liu, 2016
Oleanolic acid (OA) is a natural triterpenoid that is widely distributed in edible and medicinal plants. OA exerts anti-tumor activity on a wide range of cancer cells primarily through inducing apoptosis. Dysregulated ERK signaling is closely complicated in the biology of cancer, such as metastasis, proliferation, and survival, and it can be activated by various stimuli. But it is not clear whether there is a connection between the OA and ERK signaling pathways.
In this study, by blocking ERK activation by U0126 or siRNAs was able to potentiate the pro-apoptotic activity of OA on cancer cells, the results showed that OA induced the activation of ERK in cancer cells. ERK activation compromised the apoptosis induced by OA. In conclusion, the researchers provided evidences that ERK activation is a mechanism underlying the resistance of cancer cells to OA-induced apoptosis and targeting ERK is a promising strategy to enhance the anti-tumor efficacy of OA.
Fig1. OA induces the activation of ERK signaling in cancer cells.
Case study 2: Yuanya Zhang, 2019
The spatiotemporal regulation of ERK activity has been extensively studied. However, scarce information has been available regarding the quality control of the kinases to scavenge malfunctioning ERKs.
Using site-specific mutagenesis and mass spectrometry, the researchers found that the disruption of the conserved H-bond between Y210 and E237 of ERK1 through point mutation at or naturally occurring nitration on Y210 initiates a quality control program dependent on chaperon systems and CHIP (C-terminal of Hsp70-interacting protein)-mediated ubiquitination and degradation. These findings clearly demonstrate how malfunctioning ERKs are eliminated when cells are in certain stress conditions or unhealthy states, and could represent a general mechanism for scavenging malfunctioning kinases in stress conditions.
Fig3. HEK293T cells expressing GFP-ERK1 (ERK1) or GFP-ERK1-Y210F (Y210F) were serum-starved overnight and then treated with the nuclear export inhibitor LMB (40 mM) or vehicle (DMSO) for 3 h as indicated.
MAPK3 involved in several pathways and played different roles in them. We selected most pathways MAPK3 participated on our site, such as MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, which may be useful for your reference. Also, other proteins which involved in the same pathway with MAPK3 were listed below. Creative BioMart supplied nearly all the proteins listed, you can search them on our site.
Pathway Name | Pathway Related Protein |
---|---|
MAPK signaling pathway | FGF2;CACNB3;RPS6KA2;TRP53;NTRK1;GADD45G;FGF13;CACNG7A;CACNA2D2 |
ErbB signaling pathway | NRG2;PAK3;PLCG2;SHC3;GSK3AA;HRASB;ABL2;SHC2;CAMK2A |
Ras signaling pathway | PLA2G4C;FGF16;RAP1B;VEGFC;KIT;MAP2K2;FGFR2;NFKB1;PTPN11 |
Rap signaling pathway | MRAS;BRAF;FGFR4;PGF;Pdgfa&Pdgfb;Itgam&Itgb2;RASSF5;Fgf15;VEGFB |
cGMP-PKG signaling pathway | VDAC1;CALM3;SLC25A31;ATF4;ATP2A3;MAP2K1;CREB3L2;IRS4;AKT1 |
cAMP signaling pathway | PIK3R1;RELA;HHIP;PLN;GLI1;VAV3;PDE4B;PPP1CB;CALM1 |
Chemokine signaling pathway | GNG3;PARD3;NFKBIA;GM10591;STAT3;CCR5;CRKL;CXCR1;PTK2 |
HIF- signaling pathway | PIK3CB;ANGPT1;RPS6KB1;EIF4E1B;EIF4E2;NOX3;PRKCG;ALDOA;TCEB2 |
FoxO signaling pathway | MDM2;PIK3CD;S1PR1;TGFBR1;PRKAG2;FASLG;IKBKB;CCND2A;ATG12 |
Sphingolipid signaling pathway | MAPK10;PPP2R5A;AKT1;MAPK11;S1PR4;PPP2R2B;SMPD1;CERS4;RAC3 |
Phospholipase D signaling pathway | GNA12;GNAS;PIK3R1;PTGFR;AGPAT4;SHC4;ARF6;AKT2;PTK2B |
Oocyte meiosis | AURKA;STAG3;RPS6KAL;CAMK2D2;MAP2K1;CTH1;BUB1;CAMK2G1;CCNB2 |
mTOR signaling pathway | IKBKB;RRAGCB;PIK3R3B;RPS6KA1;RRN3;PRR5;PIK3CD;ULK3;STK11 |
PIK-Akt signaling pathway | PPP2R5D;LAMA5;PIK3CA;GNGT1;RELA;KIT;IFNA7;IL2RA;PPP2R1B |
Adrenergic signaling in cardiomyocytes | CACNA2D1A;PLCB2;MAPK12;PPP2R2CA;PPP2R3A;ATP1B3B;CACNG3;ADCY2B;PIK3R3 |
Vascular smooth muscle contraction | PLCB3;ROCK2A;CALM;NPR2;RHOAC;KCNMA1A;Adcy4;MYL6;PLA2G4AA |
Dorso-ventral axis formation | MAP2K1;ETS2;MAPK3;SOS1;EGFRA;NOTCH1A;SPIRE2;NOTCH4;NOTCH1 |
TGF-beta signaling pathway | SMAD6;ZFYVE16;ID2A;BMPR1A;RBL1;BMP2;TGFBR1;TFDP1;LFT2 |
Axon guidance | FRS3;ABL1;GNAI1;GFRA4;UNC5C;FRS2;NTN1B;PAK4;CLASP1 |
VEGF signaling pathway | MAPKAPK3;PIK3R5;VEGFAB;PLA2G4D;RAC1A;RAF1;MAPK13;AKT2;PIK3CB |
Osteoclast differentiation | NCF2;TREM2;TGFBR2;MAP3K7;LILRB4;CSF1R;FOS;IFNGR2;TGFB1 |
Focal adhesion | PIK3R2;ITGA7;THBS3;MYL5;PXN;PRKCBB;PTK2;TNXB;MAPK1 |
Adherens junction | WASB;CSNK2A2A;WASL;FYNB;SMAD2;RAC1B;WASLA;WASF2;TGFBR2 |
Gap junction | HRAS;MAP2K1;GRB2B;TUBB5;TUBAL3;GNAI2B;GRB2A;TUBA1L;PRKCB |
Signaling pathways regulating pluripotency of stem cells | ESX1;INHBE;FZD7;ACVR1B;AXIN1;MAPK3;ID1;FGF2;WNT7B |
Platelet activation | PLCB2;MYL12A;COL24A1;PRKG1;ITGB1;GNAI2;MYLK2;P2RY12;PRKACA |
Toll-like receptor signaling pathway | IL12A;PIK3R1;CCL5;SPP1;TLR1LA;AKT2L;TNF;AKT2;IL8L1 |
NOD-like receptor signaling pathway | PSTPIP1;IL8L1;IKBKG;BIRC3;NFKBIA;IL-8;PSTPIP1B;IL1B;IL8L2 |
Natural killer cell mediated cytotoxicity | PIK3R5;NFATC1;ICAM1;CD247;PPP3CB;Casp3;IFNGR2;IFNAR1;PRF1 |
T cell receptor signaling pathway | PIK3CB;CBLB;CD8B;GRAPA;PIK3R3;NFKBIA;CD40LG;GSK3B;CD28 |
B cell receptor signaling pathway | PIK3AP1;NEDD9;CR2;DUSP6;SOS1;RELA;PDK2;LIME1;IKBKG |
Fc epsilon RI signaling pathway | RAC3;MAP2K7;GM-CSF;VAV1;RAF1;MAPK3;MAP2K4;MAPK8;PIK3CB |
Fc gamma R-mediated phagocytosis | SPHK1;PAK1;DOCK2;PLA2G4F;GAB2;PLD2;PTPRC;WASF2;MARCKS |
TNF signaling pathway | LIF;FADD;PIK3R1;NFKBIA;MAP3K7IP3;PIK3CD;TRAF5;FAS;CX3CL1 |
Circadian entrainment | GRIA3;GNG11;GNAS;GRIN2D;PLCB2;RYR3;GNGT2;PLCB3;PRKACG |
Long-term potentiation | PLCB4;ATF4;ITPR1;KRAS;GRIN1;MAP2K1;GRIN2C;CALML3;ITPR3 |
Neurotrophin signaling pathway | MAPK3;Fasl;CAMK2D;RPS6KA3;MAPK1;CAMK2A;MAP2K7;YWHAE;NFKBIA |
Retrograde endocannabinoid signaling | ITPR1;SLC17A6;GNGT2;GNGT1;GNG2;PTGS2;MAPK10;SLC17A8;DAGLB |
Glutamatergic synapse | GRIN3A;GRIK1;GRM1;GNG5;GRIK4;ADRBK2;PRKACG;GRM8;GNG7 |
Cholinergic synapse | GNGT2;CHRM2;GNB1;ITPR3;PIK3CD;CHRNB4;BCL2;HRAS;CAMK2A |
Serotonergic synapse | GNAI2;HTR3C;KCNN2;PLCB1;TRPC1;MAOB;PTGS1;HTR7;NRAS |
Long-term depression | GNAI1;GNA11;PRKCA;PLCB2;GRIA3;PLA2G4F;ARAF;PPP2R1B;PLCB3 |
Regulation of actin cytoskeleton | DIAP1;PPP1CAB;ITGA1;PDGFRB;BRK1;ARPC5A;PPP1CC;PFN2L;PTK2 |
Insulin signaling pathway | PRKACAA;TSC1B;CBL;G6PCA.2;NRAS;FBP1A;PTPRFB;PRKAA1;PRKACAB |
GnRH signaling pathway | ADCY2B;CAMK2A;RAF1B;ADCY1A;PRKCB;MAP2K4;CACNA1SB;CALM3A;MMP14 |
Progesterone-mediated oocyte maturation | MAD2L2;CDC16;MOS;PRKACG;SPDYA;MAPK12A;CDC25C;MAD2L1;ADCY2B |
Estrogen signaling pathway | KCNJ6;PRKACG;HRAS;ESR2;PRKCD;ITPR1;HSPA2;HSPA1A;NOS3 |
Melanogenesis | CALM1B;FZD3;CALM2;CAMK2B1;WNT6;Fzd4;WNT8A;PRKCG;CALM1A |
Prolactin signaling pathway | GSK3B;STAT5B;PIK3CD;TNFSF11;NRAS;MAPK3;CSH;AKT1;SOCS7 |
Thyroid hormone signaling pathway | RXRG;ITGAV;SLC9A1;MED24;TP53;PLCG1;PLCB3;PLCZ1;ACTB |
Oxytocin signaling pathway | MYL9;RYR1;NPR2;NFATC1;PIK3CB;MYLK;RYR3;PIK3R1;PPP3R2 |
Type II diabetes mellitus | SLC2A2;IKBKB;MTOR;PIK3R3;IRS2;MAFA;PRKCZ;PIK3R2;MAPK8 |
Aldosterone-regulated sodium reabsorption | HSD11B2;SFN;SCNN1B;PRKCA;KCNJ1;NR3C2;ATP1A4;PRKCB;IGF1 |
Alzheimers disease | NDUFA3;PLCB2;COX8A;FAS;ATP5F1;CYCS;SDHB;COX6B1;PPP3CA |
Prion diseases | STIP1;MAPK3;NCAM1;PRKACA;LOC100033925;C1QB;C5;C9;PRNP |
Alcoholism | HIST1H2BM;CREB3L4;HIST1H2BF;HIST1H2AP;HIST1H2AL;DRD1A;HIST1H4C;HIST1H2BJ;H3F3C |
Shigellosis | CDC42;DIAPH1;RAC1;HCLS1;IL-8;NFKBIA;ITGB1;PFN2;MAPK8 |
Salmonella infection | MAPK12B;PFN3;RAB7B;RAC1A;CASPA;NLRC4;TLR5;TLR4;FLNC |
Pertussis | CASP7;CALM2;ITGA5;NLRP3;CD14;IL12A;IRAK1;IL23;C1S |
Leishmaniasis | IL12B;HLA-DOA;FCGR1A;Itgam&Itgb2;TGFB1;HLA-DRB4;TAB2;FCGR2A;PRKCB |
Chagas disease (American trypanosomiasis) | GNAI2;MAPK13;PIK3CG;IL-8;PIK3CB;NFKBIA;CCL3L3;PIK3R5;IKBKB |
Toxoplasmosis | IRGM;LDLR;STAT3;PDPK1;HSPA1L;HLA-DPA1;MAPK11;IL10RB;HLA-DQA1 |
Tuberculosis | MAPK9;CARD9;ATP6V0A2;HLA-DRB1;FCER1G;NFYC;LAMP1;ATP6V0C;IFNG |
Hepatitis C | NFKB1;NR1H3;OAS1A;PPP2R2D;IFNA10;IKBKB;EIF2AK2;SOS1;CLDN8 |
Hepatitis B | STAT5B;IFNA21;CREB5;Ifna11;BAX;PIK3CG;BAD;CXCL8;CCND1 |
Influenza A | EIF2AK4;PRSS1;NXF1;IFIH1;RNASEL;IL6;DNAJB1;EIF2AK2;IL33 |
Pathways in cancer | STAT5A;PPARD;TGFBR2;GNG7;BMP4;LAMA4;AGTR1A;SUFU;GNB4 |
Viral carcinogenesis | HDAC3;HPN;PIK3R1;HIST1H4M;PKM;HIST1H4J;SKP2;GTF2B;PKM2 |
Proteoglycans in cancer | WNT11;WNT1;TGFB2;GPC1;Fzd4;BRAF;PIK3R5;CD63;FZD7 |
Colorectal cancer | TP53;MAPK10;MSH2;AKT2;Casp3;APC;MAP2K1;PIK3R5;GSK3B |
Renal cell carcinoma | AHA-1;PIK3R2;TGFB2;RAP1A;TGFB1;PIK3R1;PAK7;CUL2;RBX1 |
Pancreatic cancer | KRAS;AKT2;PIK3CD;SMAD2;CASP9;VEGFA;ARHGEF6;SMAD4;MAP2K1 |
Endometrial cancer | CCND1;PIK3R1;CTNNA3;BRAF;KRAS;CTNNA2;PIK3R5;AKT1;PIK3CB |
Glioma | BRAF;CALM1;PIK3CB;CAMK2B;PDGFRA;PIK3R5;CALM3;PIK3CA;SHC1 |
Prostate cancer | PDGFRA;CCNE2;TRP53;GSTP1;CREB3L2;Pdgfa&Pdgfb;FOXA1;PIK3CD;IKBKB |
Thyroid cancer | LEF1;KRAS;RXRB;MAPK1;TPM3;TPR;PPARG;CDH1;NRAS |
Melanoma | FGF4;FGFR1;PIK3CB;MET;ARAF;IGF1;TRP53;FGF18;TP53 |
Bladder cancer | MYC;HBEGF;MDM2;ERBB2;DAPK2;CDK4;THBS1;MMP1A;RAF1 |
Chronic myeloid leukemia | RUNX1;CBLC;SHC1;PIK3CA;PIK3R1;CTBP1;BCR;IKBKG;TGFB3 |
Acute myeloid leukemia | MTOR;PIK3CG;PIM2;PIK3R2;HRAS;RPS6KB1;SPI1;ARAF;PPARD |
Non-small cell lung cancer | ERBB2;MAP2K1;RASSF1;FHIT;GRB2;PRKCG;PIK3R3;HRAS;MAPK1 |
Central carbon metabolism in cancer | PIK3R3;HK1;PIK3CB;SLC16A3;PDGFRB;PIK3CG;PFKM;G6PD;ERBB2 |
Choline metabolism in cancer | PRKCB;WASF1;PDGFRB;RHEB;CHKB;PDPK1;AKT1;RAC1;DGKZ |
MAPK3 has several biochemical functions, for example, ATP binding, MAP kinase activity, phosphatase binding. Some of the functions are cooperated with other proteins, some of the functions could acted by MAPK3 itself. We selected most functions MAPK3 had, and list some proteins which have the same functions with MAPK3. You can find most of the proteins on our site.
Function | Related Protein |
---|---|
ATP binding | BLM;PAK1;FARSB;RAD51L3;NPR1A;BMPR2;CAMK1GB;GRK5;CDC6 |
MAP kinase activity | MAPK12A;MAPK3;MAPK6;MAPK4;MAPK8A;MAPK14A;MAPK14B;MAPK11;NLK1 |
phosphatase binding | SH3YL1;CARHSP1;TRPC4AP;CNST;MAST2;SLC9A3R2;PPP1R36;MAGI2;ELL |
phosphotyrosine binding | PTPN3;CBL;MAPK1;CBLC;SAMSN1;ZAP70;FGR;GRB2;LDLRAP1 |
protein binding | MPP2;GTF2IRD2;TDRD9;TBX6;PTPRJ;TCTEX1D2;AGTR1A;TRPC7;TXNDC12 |
scaffold protein binding | TREM1;CASP8;NLGN4X;NLGN4Y;VIM;PDE4D;SCN5A;DSP;SRC |
MAPK3 has direct interactions with proteins and molecules. Those interactions were detected by several methods such as yeast two hybrid, co-IP, pull-down and so on. We selected proteins and molecules interacted with MAPK3 here. Most of them are supplied by our site. Hope this information will be useful for your research of MAPK3.
DUSP1; PTPRJ; MAPK14; DHPS; Ptprr
Research Area
Related articles
- Reviews
- Q&As
Customer Reviews (3)
Write a reviewExemplary precision and unblemished dependability render it my most cherished research ally.
Presenting exceptional reliability and stability, the experimental reagent establishes a robust foundation for my experiments.
Exquisitely crafted packaging design adds convenience to the usage of this protein reagent and exudes a sense of sophistication.
Q&As (7)
Ask a questionDysregulation of MAPK3 signaling has been implicated in the pathogenesis of several diseases. Aberrant activation of MAPK3 is associated with cancer development and progression, as it promotes cell proliferation and survival. MAPK3 signaling is also involved in cardiovascular diseases, contributing to vascular remodeling and hypertrophy. In neurodegenerative diseases, dysregulated MAPK3 activity contributes to neuronal dysfunction and apoptosis.
Future research in MAPK3 aims to elucidate the intricate signaling network and identify novel regulatory mechanisms. Understanding the crosstalk between MAPK3 and other signaling pathways will be crucial for developing targeted therapies. Additionally, exploring the role of MAPK3 isoforms in different cellular contexts and disease states will provide valuable insights. Furthermore, the development of more specific and potent inhibitors with reduced toxicity profiles is a focus for future therapeutic interventions.
MAPK3, also known as ERK1 (Extracellular Signal-Regulated Kinase 1), is a serine/threonine kinase involved in cell signaling pathways. It consists of 379 amino acids and exhibits a conserved catalytic domain. MAPK3 plays a crucial role in regulating cell proliferation, differentiation, and survival by phosphorylating downstream targets such as transcription factors and other kinases.
MAPK3 signaling exerts its effects through phosphorylation of downstream targets. It phosphorylates various transcription factors, including ELK1 and c-Fos, leading to changes in gene expression. MAPK3 also phosphorylates other kinases, such as p90RSK, which further propagate the signal to regulate cellular processes like cell cycle progression, apoptosis, and differentiation.
One challenge is the potential for off-target effects when targeting MAPK3, as it is involved in multiple signaling pathways. Additionally, resistance to MAPK3 inhibitors can emerge due to compensatory signaling mechanisms and genetic alterations. Another challenge lies in achieving selective inhibition of specific MAPK3 isoforms without affecting other closely related kinases.
The activity of MAPK3 is tightly regulated by various mechanisms. Activation of MAPK3 involves dual phosphorylation of threonine and tyrosine residues by upstream kinases. Conversely, dephosphorylation by phosphatases can inactivate MAPK3. Additionally, scaffolding proteins and interacting partners can modulate its activity by facilitating or inhibiting its phosphorylation or by regulating its subcellular localization.
Inhibition of MAPK3 activity or downstream effectors represents a potential therapeutic approach. Small molecule inhibitors targeting MAPK3 kinase activity, such as U0126 and PD98059, have been developed. Monoclonal antibodies against MAPK3 or its downstream effectors are also being investigated. Combination therapies targeting multiple components of the MAPK3 signaling pathway are being explored to enhance efficacy and overcome resistance.
Ask a Question for All MAPK3 Products
Required fields are marked with *
My Review for All MAPK3 Products
Required fields are marked with *